Merrill maintains Amylin at neutral

Amylin Pharmaceuticals was kept at its neutral rating by Merrill Lynch analyst Tom McGahren on the company's pre-announced Byetta net sales for the first quarter of $68 million. Merrill believes end-user demand was closer to its estimate of $75 million, based on NDC data. The analyst widened his first quarter loss-per-share estimate to $0.51 from $0.48 pending Amylin's earnings call on April 26. Shares of the San Diego biopharmaceutical company were down $1.28, or 2.62%, at $47.64 on volume of 4,306,090 shares versus the three-month running average of 2,221,560 shares. (Nasdaq: AMLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.